Nasdaq icpt.

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...NASDAQ:ICPT opened at $19.00 on Wednesday. The company has a quick ratio of 2.52, a current ratio of 4.22 and a debt-to-equity ratio of 3.12. Intercept Pharmaceuticals has a 1-year low of $8.82 and a 1-year high of $21.86. The firm has a market capitalization of $794.77 million, a price-to-earnings ratio of -12.84 and a beta of 0.88.ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders. NEW YORK-- (BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) to Alfasigma S.p.A. for $19.00 per share i...Nov 8, 2023 · Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.04) to $1.93 per share. Intercept Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off prior year's report dates. Read More.

NASDAQ: ICPT Intercept Pharmaceuticals. The drugmaker reported strong sales growth for Ocaliva as it prepares to file for approval in what could be a blockbuster indication.WebImagine if you held Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for half a decade as the share price tanked 87%. And some of the more recent buyers are probably worried, too, with the stock ...ICPT's current price target is $23.18. Learn why top analysts are making this stock forecast for Intercept Pharmaceuticals at MarketBeat.

Market Capitalization. $794.77 million. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $23.18. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media Sustainability.Nasdaq ICPT (Intercept Pharmaceuticals) is a renowned biopharmaceutical company that has been making significant strides in the field of liver disease treatment. With a focus on developing innovative therapies, ICPT aims to address the unmet medical needs of patients suffering from various liver conditions.

Intercept's Financials. Intercept's Q1 2023 financial results showed $68.0 million in net sales, a rise from $59.2 million in Q1 2022. Operating expenses were $99.6 million, with $93.6 million as ...2023 Financial Guidance. Intercept has updated its full-year 2023 Ocaliva ® net sales guidance to $320-$340 million from $310-$340 million. In June 2023, the Company lowered 2023 non-GAAP ...While US Steel and Intercept Pharmaceuticals are lower with the broader stock market, China's Future FinTech is surgingSep 26, 2023 · Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT) Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of ...

Intercept Pharmaceuticals Inc stock price (ICPT) NASDAQ: ICPT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Intercept Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

Find the latest historical data for Intercept Pharmaceuticals, Inc. Common Stock (ICPT) at Nasdaq.com.

Intercept Pharmaceuticals ( NASDAQ: ICPT) is unlikely to see any other bidders after agreeing to a $19 per share sale to Alfasigma, according to analysts. "We also see an extremely low likelihood ...1 Back to ICPT Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Trending Stocks...Dec. 9, 2021, 11:15 AM. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has withdrawn its European marketing application seeking approval for obeticholic acid (OCA) for liver fibrosis due to ...Intercept (NASDAQ:ICPT) just announced that the FDA has set an action date of June 22nd, 2023 for its second review of Ocaliva in NASH. This prompted me to look at Intercept again. This prompted ...We feel now is a pretty good time to analyse Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) business as it appears the company may be on the cusp of a considerable accomplishment. Intercept ...Web

Dec 10, 2020 · Contacts. For more information about Intercept, please contact: Lisa DeFrancesco. +1-646-565-4833. [email protected]. Christopher Frates. +1-646-757-2371. [email protected] ... On that note, Intercept Pharmaceuticals (NASDAQ:ICPT) shares crashed in the previous year due to a CRL. In making a successful turnaround, Intercept recently sent its lead drug (obeticholic acid ...Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT) represented a bright spot, with shares swinging up 75% before slightly adding to those gains. Catapulting the ...WebNASDAQ: ICPT Intercept Pharmaceuticals. ... (ICPT) Q3 2021 Earnings Call Transcript. Intercept Pharmaceuticals, inc (ICPT) Q2 2021 Earnings Call Transcript. 523%. Premium Investing Services.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...

New data on INT-787, Intercept’s next generation FXR agonist, to be featured in two posters. MORRISTOWN, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a ...

Aug 5, 2023 · INTERCEPT PHARMACEUTICALS INC ( ICPT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ... According to the issued ratings of 8 analysts in the last year, the consensus rating for Intercept Pharmaceuticals stock is Hold based on the current 7 hold ratings and 1 buy rating for ICPT. The average twelve-month price prediction for Intercept Pharmaceuticals is $23.18 with a high price target of $54.00 and a low price target of …ICPT's current price target is $23.18. Learn why top analysts are making this stock forecast for Intercept Pharmaceuticals at MarketBeat.For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, please contact: Jeffrey P. Campisi ...(NASDAQ: ICPT). Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical Inc., including chief ...NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...Advisory Committee Meeting scheduled for May 19, 2023 PDUFA Target Action Date is June 22, 2023 MORRISTOWN, N.J., March 10, 2023 -- Intercept Pharmaceuticals, Inc. , a biopharmaceutical company... | June 15, 2023There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intercept Pharma (ICPT – Research Report), ... There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in ...Real time Intercept Pharmaceuticals (ICPT) stock price quote, stock graph, news & analysis.

MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...

9 thg 10, 2023 ... (Nasdaq: ICPT), relating to its proposed sale to Alfasigma S.p.A. Under the terms of the agreement, ICPT shareholders are expected to ...

New data on INT-787, Intercept’s next generation FXR agonist, to be featured in two posters. MORRISTOWN, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a ...Intercept Pharmaceutical (NASDAQ:ICPT) is unlikely to see any other bidders after agreeing to a $19 per share sale to Alfasigma, according to analysts. "We also see an extremely low likelihood of ...NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel ...Sep 26, 2023 · Shares of Intercept Pharmaceuticals ( ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private Italian ... MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Sep 26, 2023 · Intercept Pharmaceuticals ( NASDAQ: ICPT) is unlikely to see any other bidders after agreeing to a $19 per share sale to Alfasigma, according to analysts. "We also see an extremely low likelihood ... Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) announced on December 13 that it had submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for obeticholic ...Web211.23%. Get the latest Intercept Pharmaceuticals Ord Shs (ICPT) real-time quote, historical performance, charts, and other financial information to help you make more …BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Alfasigma’s proposed acquisition of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”) expired at 11:59 p.m. on ...Intercept Pharmaceuticals ( NASDAQ: ICPT) added ~79% pre-market Tuesday after the Italian pharmaceutical company Alfasigma agreed to acquire it for $19.00 per share in cash. The acquisition will ...5. Akebia Therapeutics Inc (NASDAQ: AKBA)Short % of Float (Jan 14, 2021): 22.93%. Short % of Shares Outstanding (Jan 14, 2021): 19.94%. Akebia is a Massachusetts-based company that is working to ...MORRISTOWN, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Web

ICPT Stock 12 Months Forecast. $19.00. (0.00% Upside) Based on 9 Wall Street analysts offering 12 month price targets for Intercept Pharma in the last 3 months. The average price target is $19.00 with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 0.00% change from the last price of $19.00. NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...May 11, 2023 · Fintel reports that on May 22, 2023, Baird maintained coverage of Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform recommendation. Analyst Price Forecast Suggests 160.70% Upside AbCellera Biologics (NASDAQ:ABCL) shares made a new 52-week low of $40.09 on Monday. The stock was down 3.05% for the day. Intercept Pharmaceuticals (NASDAQ:ICPT) stock set a new 52-week low of ...WebInstagram:https://instagram. after hours marketautozoinewhere to buy elon coinvision insurance louisiana Intercept Pharmaceuticals (NASDAQ:ICPT) lost ~26% in the morning hours Wednesday after the FDA issued briefing documents as a panel of its independent advisors are scheduled to meet later this ...Find the latest analyst research for Intercept Pharmaceuticals, Inc. Common Stock (ICPT) at Nasdaq.com. ... Based on analysts offering 12 month price targets for ICPT in the last 3 months. best wall street prep coursesbest dental plans in florida Fintel reports that on July 13, 2023, HC Wainwright & Co. upgraded their outlook for Intercept Pharmaceuticals (NASDAQ:ICPT) from Sell to Buy.. Analyst Price Forecast Suggests 31.12% Upside. As of ... rivian tax credit Italy-based Alfasigma has agreed to acquire Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for $19.00 per share in cash.. The purchase price represents a premium of 82% to Intercept's closing stock ...NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the developmen...Market traders watched Intercept's recent clinical trial with anticipation. Unfortunately, the results fell short and ICPT stock is tanking. ICPT stock investors are concerned about disappointing clinical trial results Source: Postmodern St...